IsoTis Adjourns Special Meeting to October 26, 2007
Irvine, California (ots/PRNewswire)
- Less Than 350,000 Additional Votes "FOR" Required for Integra Merger
IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company,
today announced that it has adjourned the special meeting of
stockholders again, to October 26, 2007, to approve the acquisition
of IsoTis by Integra LifeSciences Holdings Corporation (NASDAQ: IART)
("Integra") pursuant to an agreement and plan of merger dated as of
August 6, 2007.The special meeting of stockholders will now be held at 7 a.m. Pacific time on October 26, 2007 at IsoTis' offices of Latham & Watkins at 650 Town Center Drive, 20th floor, Costa Mesa, CA.
In order hold the special meeting, a majority of IsoTis' 7,099,229 outstanding shares (i.e., 3,549,615 shares) must be present at the meeting in person or by proxy. An insufficient number of shares were present at today's reconvened meeting to conduct the meeting. Of the 3.4 million shares present, approximately 3.2 million voted "for" the merger with Integra, representing 94.3% of the votes cast to date, and 45.5 % of all outstanding shares at the record date.
Based on recent communications with custodians and brokers, IsoTis is cautiously optimistic that it will be able to solicit the additional approximate 350,000 shares before the newly adjourned meeting recommences on October 26, 2007. Should this not turn out to be the case, IsoTis may adjourn the meeting again, or may consider calling a new meeting in November 2007 with a new record date for the stockholders entitled to vote. By setting a new record date, IsoTis would allow all stockholders, including those who have acquired shares since the current meeting's record date of August 24, 2007 or those who will acquire shares before a new record date, an opportunity to vote on the Integra transaction.
IsoTis also announced today that its primary creditor, Merrill Lynch, has agreed to extend the deadline for IsoTis to repay funds borrowed under its credit line from October 31, 2007 to November 30, 2007.
The IsoTis Board of Directors continues to believe unanimously that the interests of IsoTis' stockholders are best served by the acquisition by Integra, and that there are no feasible alternatives for the company and its stockholders. If IsoTis is unable to obtain the vote necessary to approve the proposed transaction, the company believes it will have to seek bankruptcy protection.
About IsoTis
IsoTis is an orthobiologics company that develops, manufactures and markets proprietary products for the treatment of musculoskeletal diseases and disorders. IsoTis' current orthobiologics products are bone graft substitutes that promote the regeneration of bone and are used to repair natural, trauma-related and surgically-created defects common in orthopedic procedures, including spinal fusions. IsoTis' current commercial business is highlighted by its Accell line of products, which the company believes represents the next generation in bone graft substitution.
On August 7, 2007 Integra and IsoTis announced that they have reached a definitive agreement to create a global orthobiologics leader. The combination would create a comprehensive orthobiologics portfolio, one of the largest sales organizations focused on orthobiologics in the US, and multiple cross-selling opportunities. The transaction is subject to approval of IsoTis' stockholders, as well as other closing conditions and approvals. Upon closing, IsoTis will become a wholly-owned subsidiary of Integra and Integra will be one of the largest companies in the world focused on advanced technology in orthobiologics.
Forward-Looking Statements
Certain statements in this press release are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including those that refer to management's plans and expectations for, among other things, future operations, strategies, prospects, performance and financial condition and IsoTis' proposed acquisition by Integra. Words such as "strategy," "expects," "plans," "anticipates," "believes," "may," "will," "might," "could," "would," "continues," "estimates," "intends," "pursues," "projects," "goals," "targets" or the negative or other variations thereof and other words of similar meaning are intended to identify such forward-looking statements. One can also identify them by the fact that they do not relate strictly to historical or current facts. Such statements are based on the current expectations and projections of the management of IsoTis only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of IsoTis. Actual results could differ materially from current expectations and projections. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. IsoTis undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
A special stockholder meeting was convened on October 11, 2007, adjourned to October 23, 2007 and again adjourned to October 26, 2007 to obtain stockholder approval of the proposed transaction. IsoTis has filed with the Securities and Exchange Commission and distributed to its stockholders a definitive proxy statement and other relevant documents in connection with the special stockholder meeting for the proposed transaction. IsoTis stockholders are urged to read the definitive proxy statement and other relevant materials when they become available because they will contain important information about IsoTis, Integra and the proposed transaction. Investors may obtain a free copy of these materials and other documents filed by IsoTis with the Securities and Exchange Commission at the SEC's website at http://www.sec.gov, at IsoTis' website at http://www.isotis.com or by sending a written request to IsoTis at 2 Goodyear, Irvine, California 92618, Attention: Chief Financial Officer.
IsoTis and its directors, executive officers and certain other members of management and employees may be deemed to be participants in soliciting proxies from its stockholders in favor of the proposed merger. Information regarding the persons who may, under the rules of the SEC, be considered to be participants in the solicitation of IsoTis' stockholders in connection with the proposed transaction will be set forth in IsoTis' revised definitive proxy statement for its special meeting. Additional information regarding these individuals and any interest they have in the proposed transaction is set forth in the revised definitive proxy statement when it is filed with the SEC.
Contact:
For information contact: Rob Morocco, CFO, +1-(949)-855-7155,
robert.morocco@isotis.com; Hans Herklots, Director IR,
+1-(949)-855-7195
or +41-(21)-620-6011, hans.herklots@isotis.com